VISTAGEN THERAPEUTICS, INC. Research and Development in Process
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Research and Development in Process of $5.60 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2021-08-12
- VISTAGEN THERAPEUTICS, INC. research and development in process for the quarter ending 2021-06-30 was $5.60M, a 223.68% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. research and development in process for the quarter ending 2020-06-30 was $1.73M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 181 month | Research and Development in Process 184 month |
|---|---|---|---|
| 2021-06-30 | $5.60M 10-Q · filed 2021-08-12 | ||
| 2020-06-30 | $1.73M 10-Q · filed 2021-08-12 | ||
| 2014-03-31 | $7.52M 10-K · filed 2014-06-25 | ||
| 2013-12-31 | $7.52M 10-Q · filed 2014-02-14 | ||
| 2013-09-30 | $7.52M 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |